Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Chengdu Kanghong Pharmaceutical Group Co., Ltd. ("Kanghong Pharmaceutical" or the "Group") was founded in 1996 and is a pharmaceutical group dedicated to the R&D, production, sales and after-sales service of biological products, traditional Chinese medicines, chemical drugs and medical devices, with advanced R&D centers and standardized industrial production bases and a marketing network covering the whole country. On June 26, 2015, Kanghong Pharmaceutical was officially listed on the Shenzhen Stock Exchange (stock code: 002773). The Group has built a product layout with "Kanghong characteristics" in ophthalmology, major psychiatric/neurological diseases, chronic disease prevention and treatment such as hypertension and diabetes, and the treatment of common and frequently occurring diseases such as respiratory and gastroenterology. Among its 25 currently marketed drugs, 10 are exclusive varieties, 20 are included in the national medical insurance catalog, and 11 are included in the national essential drugs catalog.

Chengdu Kanghong Pharmaceutical Group Co., Ltd. was founded in 1996 as a pharmaceutical group dedicated to the R&D, production, sales and after-sales service of biological products, traditional Chinese medicines, chemical drugs and medical devices. On June 26, 2015, it was officially listed on the Shenzhen Stock Exchange (stock code: 002773). Its product 康柏西普眼用注射液 (Kangbaxi Pu eye injection) is described as a landmark product of Chinese pharmaceutical innovation and China's first original Class I biological new drug to obtain a WHO International Nonproprietary Name (INN); it was first launched in China in March 2014, filling the market gap for domestic fundus macular degeneration treatment drugs and breaking the monopoly of high-priced imported drugs in China's ophthalmic market. In March 2016 it was named "Most Clinically Valuable Innovative Drug"; in December 2017 its substance patent won the China Patent Gold Award; and on December 9, 2018, the project "Development of the National Class I New Drug Kangbaxi Pu Eye Injection" won the Fifth "China Industrial Award," China's highest award in the industrial field. The Group's 舒肝解郁胶囊 is described as the first traditional Chinese medicine new drug approved in China for the treatment of mild to moderate depression, included in more than 60 guidelines and consensus documents including the Chinese Guidelines for the Prevention and Treatment of Depressive Disorders, included in the Chinese Pharmacopoeia, and a national second-class protected traditional Chinese medicine variety. In gene therapy, KH631 eye injection and KH658 eye injection are Class 1 biological new drugs for neovascular (wet) age-related macular degeneration (nAMD), both at China Phase II and U.S. Phase I stages. In synthetic biotechnology, 注射用KH617 is a self-developed Class 1 innovative chemical drug for patients with advanced solid tumors (including adult diffuse glioma), at Phase II stage, and received FDA orphan drug designation for glioblastoma. In antibody-drug conjugates, Kanghong developed KH815, described as the world's first dual-payload ADC to enter clinical trials, at Phase I stage in both China and Australia.

A pharmaceutical group pursuing technological progress and product innovation, building corporate competitiveness centered on innovative drug R&D, with the stated aim of becoming one of China's most outstanding pharmaceutical groups.

• 朗沐® (康柏西普眼用注射液)

  Described as a landmark product of Chinese pharmaceutical innovation and China's first original Class I biological new drug to obtain a WHO International Nonproprietary Name (INN); launched in China in March 2014; over 5 million injections completed in 11 years on market.

• 舒肝解郁胶囊

  Described as the first traditional Chinese medicine new drug approved in China for mild to moderate depression; included in more than 60 guidelines and consensus documents and the Chinese Pharmacopoeia; a national second-class protected TCM variety.

• KH631 eye injection

  A Class 1 biological new drug with independent intellectual property for neovascular (wet) age-related macular degeneration (nAMD), based on an AAV delivery system; at China Phase II and U.S. Phase I stages.

• KH658 eye injection

  A gene therapy product for nAMD using a novel AAV vector designed based on cell-specific receptors; at China Phase II and U.S. Phase I stages.

• 注射用KH617

  A self-developed Class 1 innovative chemical drug for advanced solid tumors (including adult diffuse glioma), at Phase II stage, with FDA orphan drug designation for glioblastoma.

• KH815

  Described as the world's first dual-payload antibody-drug conjugate (ADC) to enter clinical trials; at Phase I stage in both China and Australia.

• 右佐匹克隆片（伊坦宁）

  Passed consistency evaluation on February 21, 2020; newly included in the National Essential Drugs List (2026 edition).

• 枸橼酸托法替布缓释片（诺泰欣）

  Newly included in the National Essential Drugs List (2026 edition).

• 博思清阿立哌唑口服溶液

  National launch meeting held on April 23, 2020.

1. 1成都康弘药业集团股份有限公司_康弘药业cnkh.com
2. 2集团简介_康弘药业cnkh.com
3. 3康弘药业_走进康弘_康弘药业cnkh.com
4. 4康弘药业_走进康弘_康弘药业cnkh.com
5. 5Chengdu Kanghong Biotech Co., Ltd. (China)wikidata.org